Neurocrine Biosciences
NBIX
#1588
Rank
S$16.65 B
Marketcap
S$165.91
Share price
-0.77%
Change (1 day)
13.14%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): S$5.61

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is S$5.51. In 2024 the company made an earnings per share (EPS) of S$4.32 an increase over its 2023 EPS that were of S$3.25.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$5.6129.86%
2024S$4.3233.07%
2023S$3.2557.76%
2022S$2.0669.47%
2021S$1.22-78.21%
2020S$5.58990%
2019S$0.5181.82%
2018S$0.28-113.5%
2017S-$2.090.62%
2016S-$2.0757.28%
2015S-$1.3225.61%
2014S-$1.0518.84%
2013S-$0.88-1085.71%
2012S$0.08955

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
S$1.74-68.45%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$3.06-44.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$29.45 434.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
S$0.03838-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
S-$2.60-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$2.19-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
S-$38.25-793.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$2.26-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK